Latest Biotech News

WHO declared the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo a public health emergency of international concern, escalating an outbreak now spreading across DRC and reaching...

Collaborative Drug Discovery expanded its AI collaboration with Eli Lilly by planning tighter integration of Lilly TuneLab predictive models into CDD Vault workflows. The agreement targets ADMET...

Researchers published a multimodal AI framework intended to improve breast cancer prognostication, combining multiple data sources into a single predictive approach. The study, led by Witowski,...

Parabilis filed for an IPO to fund development of its Wnt/β-catenin pathway inhibitor zolucatetide for desmoid tumors, shortly after inking a research collaboration with Regeneron. The IPO filing...

Regeneron and Parabilis announced a collaboration worth up to roughly $2.3 billion to develop Antibody-Helicon Conjugates aimed at historically undruggable intracellular targets. The program...

Diasorin said the FDA granted 510(k) clearance for a customizable syndromic GI pathogen PCR panel built for its Liaison Plex platform. The Liaison Plex Gastrointestinal Flex Assay detects 24...

Immunovant’s IMVT-1402 FcRn inhibitor produced “really great” responses in an ongoing Phase 2b open-label dataset in difficult-to-treat rheumatoid arthritis, according to CEO Matt Gline. Shares...

San Diego startup cAMPfield Therapeutics raised $180 million in a Series A, according to the announcement, positioning the company to develop inflammatory and immunology therapies built on...

Parabilis Medicines moved to the public markets, filing for an IPO days after signing a major strategic research collaboration with Regeneron to pursue “undruggable” targets. The Regeneron deal...

Guardant Health said the FDA has approved its upgraded Guardant360 Liquid CDx, a blood-based liquid biopsy intended to guide treatment decisions in advanced cancer. The company said the test...

Personalis said CMS expanded Medicare coverage for its NeXT Personal minimal residual disease (MRD) test to include monitoring response to neoadjuvant treatment in patients with stage II to III...

Mekanistic Therapeutics reported that the FDA cleared an IND for MTX-531, the company’s lead oncology candidate, marking the start of a Phase 1 study in patients with advanced solid tumors...

Create Medicines secured $122 million in a Series B financing to advance therapies using mRNAs delivered via liquid nanoparticles to express CARs in multiple immune-cell types inside patients. The...

Eli Lilly agreed to acquire Engage Biologics in a deal valued at $202 million, expanding its genetic medicines pipeline with Engage’s non-viral DNA delivery platform. The preclinical biotech...

Incyte expanded its AI partnership with Edison Scientific, paying $80 million upfront to broaden use of Edison’s platform across additional drug-discovery targets. The collaboration centers on...

Qiagen said it is working with Nvidia to integrate Nvidia BioNeMo and accelerated computing into Qiagen Digital Insights’ curated biomedical knowledgebases. The goal is to enable greater use of AI...

The WHO declared the Ebola outbreak in the Democratic Republic of Congo a public health emergency of international concern, citing confirmation of the Bundibugyo species and a high positivity rate...

Capsida Biotherapeutics said it has closed its SYNRGY Phase I/II gene therapy trial for STXBP1 after a child death following infusion of CAP-002, with the company reporting cerebral edema as the...

Personalis said the US Centers for Medicare and Medicaid Services expanded coverage for its NeXT Personal minimal residual disease (MRD) test to include monitoring response to neoadjuvant...

Regeneron entered a multi-target strategic collaboration with Parabilis Medicines built around the Helicon peptide platform, committing payments and equity investment that could total about $2.3...